Skip to content
Medical Health Aged Care

Dementia confirmed as Australia’s leading cause of death, ABS data reveals

Dementia Australia 3 mins read

The latest data from the Australian Bureau of Statistics (ABS) released today in the Causes of Death, Australia, 2024 report has named dementia as the leading cause of death in Australia, overtaking ischaemic heart diseases. 

In 2024, dementia accounted for 9.4 per cent of all deaths, whilst the number of deaths caused by dementia has increased by 39 per cent over the last decade.

Dementia has been the leading cause of death for Australian women since 2016, with the 2024 data showing that 62.4 per cent of people who died from dementia were women.

Dementia Australia CEO Professor Tanya Buchanan said this data reinforces the critical need to invest in public health approaches to brain health and dementia risk reduction, while providing more targeted support for people impacted by dementia.

“There are currently an estimated 433,300 Australians living with dementia and without significant intervention, this number is expected to increase to more than one million by 2065,” Professor Buchanan said.

“We need to act on dementia now. At a community level, we need to increase awareness of dementia and brain health, reducing the stigma experienced by so many impacted by dementia.

“Across health, aged, disability and community care sectors, we need to ensure quality dementia care, with palliative care tailored to the needs of people living with dementia, their families and carers at the end of their life.

“Although there are things we cannot change, like getting older or genetics, we now know that up to 45 per cent of dementia cases globally could be prevented or delayed by addressing modifiable risk factors.

“Dementia Australia is continuing to advocate to Government for investment in a national brain health and risk reduction campaign. We also support all Australians impacted by dementia.”

The data released by the ABS, follows the latest update of the Australian Institute of Health and Welfare’s (AIHW) Dementia in Australia report published in September this year that also reported dementia as the leading cause of death for Australians.

For more details on the ABS report, visit their website here

For dementia information and support contact the National Dementia Helpline on 1800 100 500 or visit dementia.org.au

-Ends-

Dementia Australia is the source of trusted information, education and services for the estimated more than 433,300 Australians living with dementia, and the more than 1.7 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

Media contacts: Catherine McCarthy, Media and Communications Advisor, [email protected], 0466 796 201,

Andrea Hogan, Media Relations and Communications Manager, [email protected], 0406 904 118

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:
We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:


If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au. 

Media

More from this category

  • Medical Health Aged Care
  • 03/03/2026
  • 02:26
Tilray Brands, Inc.

Tilray Brands Acquires BrewDog, a Leading Global Craft Brand, Creating a ~$500 Million Global Craft Beer and Beverage Platform

Accretive Acquisition of Select Assets Includes Global Brand, UK Brewing Operations and 11 Strategic Brewpubs Expected to Generate ~$200 Million in Annual Net Revenue and ~$6 - $8 Million of Adjusted EBITDA in Fiscal 2027Tilray’s Global Consolidated Net Revenue Expected to Reach ~$1.2 Billion on an Annualized Basis1Conference Call Scheduled for 12:30pm ETNEW YORK and LONDON, March 02, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today completed the acquisition of certain highly…

  • Medical Health Aged Care
  • 02/03/2026
  • 23:11
SBC Medical Group Holdings Incorporated

SBC Medical Appoints Sheng-FU Hsiao as CTO Leveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure

IRVINE, Calif.–BUSINESS WIRE– SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services…

  • Contains:
  • Medical Health Aged Care
  • 02/03/2026
  • 18:11
Takeda Pharmaceutical Company Limited

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal StudySubmission Primarily Based on Phase 3 VERIFY Study, in Which Rusfertide Plus Standard of Care More Than Doubled Clinical Response Rates, as Well as Four-Year Efficacy and Safety Data from Phase 2 REVIVE/THRIVE StudiesPrescription Drug User Fee Act (PDUFA) Target Action Date is in the Third Quarter of this Calendar Year OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--BUSINESS WIRE-- Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.